The Facts
- University College London researchers tested a new type of gene therapy, AMT-130, on 29 patients with early-stage Huntington's disease and found it delayed symptom progression by 75% after three years of follow-up.
- The treatment, developed by uniQure, involves 12 to 18 hours of brain surgery where a modified virus delivers DNA to the caudate nucleus and putamen regions, instructing cells to reduce production of toxic huntingtin protein.
- The trial measured disease progression using the Unified Huntington's Disease Rating Scale, showing patients experienced a 0.38 reduction compared to a 1.52 reduction in historical control data over 36 months.
Sources Split
LEFT
CENTER
RIGHT
+1
+1
+4
ESTAB
CRIT
CENTER
PRO
ESTAB
The Spin
Techno-optimist narrative
This is the first successful treatment to slow the progression of Huntington's disease after decades of failed attempts. The 75% reduction in disease advancement means patients can maintain independence and quality of life for years longer than previously possible. One patient even returned to work after undergoing medical retirement, proving that this therapy delivers real-world benefits beyond clinical measurements.
Techno-skeptic narrative
While promising, this expensive treatment requiring complex 18-hour brain surgery will remain inaccessible to most patients who desperately need it. The results are based on only 29 patients without peer review, and the therapy doesn't cure the disease but merely delays the inevitable, gradual decline. Gene therapies often carry hefty price tags that healthcare systems struggle to afford, further exacerbating inequalities in access to care.
Metaculus Prediction
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.17.1